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Introduction
Coronavirus disease 2019 (COVID-19), caused by a new 
coronavirus (SARS-CoV-2, severe acute respiratory syn-
drome coronavirus 2), is a highly contagious disease that 
first appeared in Wuhan, China, in December 2019 [1]. On 
30 January 2020, the World Health Organisation (WHO) 
declared that the COVID-19 outbreak constituted a public 
health emergency of international concern (PHEIC) [2, 3]. On 
11 March 2020, the WHO officially declared a pandemic [3].
Most infected patients have mild symptoms including 
fever, fatigue, and cough [1, 4]. However, severe cases 
can progress rapidly and develop adult respiratory distress 
syndrome (ARDS) with coagulopathy [1, 4]. The latter is al-
ready described as one of the most important independent 
poor prognostic factors [5, 6]. Thus, the objective of this 
investigation was to analyse the coagulation alterations 
produced by COVID-19, and assess whether they present 
different characteristics to the coagulopathy present in 
other pathologies.
Methods
From the Haemostasis and Coagulation Laboratory, we 
selected 15 consecutive patients who had D-dimer values 
at least four times higher than normal (0.1–0.5 µg/mL), 
positivity by polymerase chain reaction (PCR) of SARS-CoV-2, 
and pneumonia on chest radiography. All of them were 
admitted during March 2020 to the Mostoles University 
Hospital (Madrid), which cares for a population of approxi-
mately 169,000 patients. During the months of March and 
April, the number of new patients with COVID-19 pneumonia 
admitted to the Hospital was 515 and 358, respectively.
All patients, coinciding with a scheduled extraction, 
had a blood sample drawn to determine basic coagulation 
parameters such as the prothrombin time ratio (PT ratio), 
activated partial thromboplastin time ratio (APTT ratio), 
thrombin (TT), D-dimer and fibrinogen. In addition, the von 
Willebrand factor (vVF:Ag and vWF:Rco), blood group ABO, 
natural anticoagulants such as antithrombin (AT), protein 
C and protein S, were analysed, and coagulation factors 
II, V, VII, VIII, IX, X, XI, and XII were dosed. All of the deter-
minations were made using STA Compact MAX and R MAX 
analysers, along with their original reagents (Diagnostica 
Stago, Saint-Denis, France). A clot solubility assay in 5M 
urea was performed as a factor XIII deficiency screening 
method. The determination of lactate dehydrogenase, 
C-reactive protein (Cobas Roche with its original reagents) 
and ferritin (ECLIA electrochemiluminescence) were also 
included in the analysis.
In addition, we collected demographic data of the pa-
tients (age and sex), the number of hospital admission days 
at the time of sample extraction, the occurrence of throm-
botic events such as pulmonary thrombosis diagnosed by 
imaging test [angiography computed tomography (angio-
CT)], and data showing if they were previously receiving 
antithrombotic prophylaxis. Moreover, the severity of the 
patients’ infectious picture, the appearance of other related 
complications, and information determining if eventually 
the patient improved or died, were also acquired.
Results
Out of the 15 patients included in the study, seven were 
women and eight were men, with a median age of 63 
years (range 30–86). Median days of hospitalisation at 
the time of sample collection was 6 (range 1–12) (Table I). 
All patients presented pneumonia confirmed by chest 
radiography from admission; 11 of them required invasive 
mechanical ventilation in the Intensive Care Unit. Before 
admission, none of them were on anticoagulant treatment. 
Prophylactic low-molecular-weight heparin (LMWH) was 
prescribed at standard doses (40 mg of enoxaparin per 
day) from the moment of admission, except for two patients 
who empirically received anticoagulant doses because they 
presented D-dimer levels 20 times higher than normal 
(0.1–0.5 µg/mL); and one who did not receive it due to 
thrombocytopenia (22 ×103/µL platelets).
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10 of the 15 patients underwent angio-CT after observ-
ing the elevation of D-dimer, and six of the 10 (60%) had 
peripheral pulmonary thrombosis. As previously discussed, 
5/6 patients were receiving prophylactic LMWH at standard 
doses prior to diagnosis. The remaining patient did not re-
ceive it, because at the time of admission he had throm-
bocytopenia of 22 ×103/µL, presenting a thrombotic event 
48 hours after it. This patient, who was diagnosed with es-
sential thrombocythemia, presented a multiple ischaemic 
stroke with subsequent haemorrhagic transformation, as 
well as an acute myocardial infarction.
Subsequently, eight patients died as a result of COVID-19 
lung infection, five were definitively discharged, and two 
remain in long-stay hospitals for recovery at the time of 
writing this review (Table I).
D-dimer values at the time of the study were between 
2.39 and 172.33 µg/mL (median 16.39 µg/mL); signifi-
cantly higher in relation to the DD value on admission 
day (median 0.86 µg/mL, range 0.47–13.19 µg/mL). The 
platelet count was within normality in 80% of the patients 
and slightly decreased in the rest (>80 ×103/µL). The PT 
ratio was also normal, except for one patient in whom the 
determination after the admission figure was normalised. 
Fibrinogen was above the upper limit of normality in 85.7% 
of patients (12/14), while in the rest it was normal, and the 
APTT ratio was normal or shortened. The TT was normal, ex-
cept in three patients due to the effect of LMWH (Table II).
None of the patients included in the study met DIC 
criteria. No significant decrease in AT, PC and PS was ob-
served. Only one patient had a slightly decreased deter-
mination of AT (76%) and PC (64%), and another of co-
agulative PS (51%). In both patients, the determination 
was made in the context of a pulmonary thrombosis diag-
nosed by angio-CT, so the decrease was not measurable 
given the consumption of coagulation factors in the acute 
thrombotic event.
A highly increased factor VIII and vWF (medians of 
267% and 466.5% respectively) were found in all patients. 
The blood group was tested in 14 patients, with nine of 
them being from blood group A, four from group O, and 
one from group B. No significantly higher values of factor 
VIII or vWF were observed in the non-O groups compared 
to the O group.
We did not observe a significant decrease in the rest of 
the coagulation factors, with the exception of four patients 
who presented a minimal decrease in factors II and V, and 
one patient in factor XII (Table II).
Discussion
The main finding of our study was that there is no factor 
consumption, nor a decrease in natural anticoagulants, 
while all the patients presented a factor VIII and a vWF 
greatly increased, reflecting the state of hypercoagulability 
they presented, although this assertion is just a hypothesis 
that requires further investigation.
These findings are in contrast to findings reported in 
other studies about coagulopathy in infectious diseases. 
As observed in our study, the alterations found in patients 
with severe SARS-CoV-2 infection are different from the co-
agulopathy found in disseminated intravascular coagulation 
(DIC) [7]. This finding is reflected in the constant observa-
tion that platelet counts and fibrinogen concentrations do 
not decrease significantly in patients with COVID-19, de-
spite the marked increase in D-dimer concentrations [8, 9].
However, given the sparse knowledge that we still have 
about the SARS-CoV-2 infection, we believe that the analyti-
cal alterations do not offer a good reflection of the altera-
tions at the local level. Whether microthrombosis exists at 
this level is beyond the scope of this study.
We do not have a real incidence of thrombotic events. 
In our study, six patients were diagnosed with pulmonary 
thrombosis after requesting imaging tests. Some of the 
remaining patients may also have it, but it is an event that 
has not been confirmed. At the present time, a retrospective 
study is underway, organized by Dr. Llamas Sillero, Head 
of Haematology Department of Fundacion Jimenez Diaz 
University Hospital (Madrid), and endorsed by the Madrid 
Society of Haematology, which aims to make an accurate 
estimation of them in the Community of Madrid.
Thus, the concept of pulmonary intravascular coagu-
lopathy (CIP) seems correct to us [9] for this condition with 
activation of coagulation located in the lung, where an en-
vironment of hypercoagulability occurs, not caused directly 
by the virus, but rather secondary to three triggers:
1) inflammation, both produced by cellular damage 
caused by cells damaged by the virus (type II pneumo-
cytes), as well as secondary to innate immunity. This 
inflammation would activate coagulation through tis-
sue factor expressed by macrophages, neutrophils, 
Table I. Clinical characteristics of patients
Parameter Value
Age Median 63 years (range 30–86)





6 (60%) pulmonary thrombosis
1 (6.7%) ischaemic stroke




Clinical evolution 7 (46.7%) death
5 (33.3%) hospital discharge
3 (20%) ICU
ICU — Intensive Care Unit
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endothelium, platelets and extracellular vesicles, phos-
phatidyl serine, free DNA, damage-associated molec-
ular patterns (DAMPs), extracellular neutrophil traps 
(NETs) or platelet activation;
2) the endothelial lesion, which loses its protective layer 
and alters its regulatory function of fibrinolysis in order 
to avoid the formation of thrombi on its surface, and its 
regulatory function of vascular permeability. In addition, 
there is direct endothelial damage from the virus since 
the endothelium, like type II pneumocytes, also has an-
giotensin-converting enzyme (ACE2R) receptors [10];
3) hypoxia that causes cellular damage and regulates 
coagulation and fibrinolysis through hypoxia-inducible 
transcription factors (HIFs) [11].
The role of immunothrombosis in containing bacte-
ria is well known, but its role in viral infections is not well 
understood [9]. In any case, when it occurs excessively, as 
is happening in many of the patients with SARS-CoV-2 pneu-
monia, it can be more harmful than the virus itself.
Conclusions
After analysing the results of the referred determinations, 
we can establish:
 ■ classical DIC does not occur in COVID-19 associated 
coagulopathy (CAC). There is no consumption of fac-
tors, nor a decrease in natural anticoagulants. There 
is a significant increase in factor VIII and vWF, due 
to extensive endothelial injury, which seems to play 
a leading role in pulmonary microthrombosis, and in 
injury to other affected organs (heart, kidneys, small 
intestine);
Table II. Laboratory parameters
Parameter Reference range n Median (min–max) < lower limit 
Reference
> upper limit 
Reference
LDH 135–225 U/L 15 479 (227–768) 0 (0%) 15 (100%)
Ferritin 50–220 ng/mL 15 1,544 (394–6,230) 0 (0%) 15 (100%)
CRP 0–5 mg/L 15 239.4 (0.7–598.8) 0 (0%) 14 (93.3%)
Platelets 150–450 ×103/µL 15 294 (81–426) 3 (20%) 0 (0%)
PT ratio 0.9–1.25 15 1.12 (1–1.31) 0 (0%) 1 (6.7%)
APTT ratio 0.86–1.18 15 0.93 (0.8–1.04) 2 (13.3%) 0 (0%)
Fibrinogen 200–400 mg/dL 14 535.5 (201–848) 0 (0%) 12 (85.7%)
D-dimer on admission 0.1–0.5 µg/mL 13 0.86 (0.47–13.2) 0 (0%) 11 (84.6%)
D-dimer at time of study 15 16.39 (2.39–172.3) 0 (0%) 15 (100%)
TT 16–21 s 12 18.75 (16.4–27.1) 0 (0%) 3 (25%)
Factor II 70–120% (95%) 15 104 (66–129) 2 (13.3%) 1 (6.7%)
Factor V 70–120% (95%) 15 113 (52–122) 2 (13.3%) 5 (33.3%)
Factor VII 55–170% (112.5%) 15 99 (55–183) 0 (0%) 3 (20%)
Factor X 70–120% (95%) 15 106 (77–135) 0 (0%) 4 (26.7%)
Factor VIII 60–150% (105%) 15 267 (128–383) 0 (0%) 15 (100%)
vWF:Ag 50–150% (100%) 12 406.5 (255–420) 0 (0%) 12 (100%)
vWF:Rco 50–200% (125%) 10 236 (from 156 to >200) 0 (0%) 7 (46.7%)
Factor IX 60–150% (105%) 15 151 (107–225) 0 (0%) 8 (53.3%)
Factor XII 60–150% (105%) 15 101 (35–139) 1 (6.7%) 0 (0%)
Factor XIII* 15 Negative 15 (100%)
AT III 80–120% (100%) 15 115 (76–135) 1 (6.7%) 5 (33.3%)
PC 70–130% (100%) 15 99 (64–181) 1 (6.7%) 3 (20%)




















APC ratio ≥2.9 13 3.58 (3.27–4.34) 0 (0%)
*Clot solubility assay in urea 5M; LDH — lactate dehydrogenase; CRP — C-reactive protein; PT — prothrombin time; APTT — activated partial thromboplastin time; TT — thrombin time; vWF — von Willebrand factor; 
Ag — antigen; Rco — ristocetin cofactor; AT — antithrombin; PC — protein C; PS — protein S; f; APC — activated protein C ratio
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 ■ the elevation of D-dimer suggests that there is local 
coagulation activation in the lung, where fibrinolysis 
is increased, but with an overall balance in favour of 
thrombosis;
 ■ what analytics ‘globally’ reflects does not seem to repre-
sent what is happening at the local level. In the places 
where microthrombosis is taking place, it is very likely 
that the levels of factors and anticoagulants are dif-
ferent from those found in this study, which points to 
the idea of a different haemostatic microenvironment.
Regarding the anticoagulation in these patients, given 
the extensive endothelial injury, we suggest that heparin, 
which apart from being an anticoagulant can also protect 
the endothelium [8] which is especially affected in this 
pathology, would be, given the data available so far, the 
chosen anticoagulant drug for both thromboprophylaxis 
and for the treatment of established venous thrombo-
embolism (VTE) [8, 12], at least in the acute moment. It 
will be interesting to observe the outcomes of patients 
who, for various reasons, have been treated with direct 
anticoagulants.
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